In this index, \( f \) denotes figure, \( s \) denotes sidebar, and \( t \) denotes table.

A

AAC. See Augmentative or alternative communication (AAC)
Abandoned utterances, 200
ABCD. See Arizona Battery for Communication Disorders of Dementia (ABCD)
ABS. See Affect Balance Scale (ABS)
Abstract letter identification, 16f, 17
Accommodations. See also Compensatory strategies; Interpreters; Modifications, 122, 129, 131–132, 149, 152
Accreditation agencies, 122, 279, 281, 283
Acetylcholine. See also Cholinergic system, 397s, 402
Achromatopsia, 55t, 73, 152
Acoustic environment, 448–449
Acoustic-phonological conversion, 15, 16f
Acquired dysgraphia, 41
Acquired dyslexia, 40–41
Acquired immune deficiency syndrome (AIDS), 93
Activity and participation. See also Assessments of activity, participation, and quality of life, 3–4, 5, 488
Activity-focused treatment. See also Participation-focused treatment, 412–425, 426f, 427–451
Acupuncture, 461–462
Acute-care settings
  assessment goals in, 117, 117t
  assessment restrictions in, 135, 136
  hidden deficits due to, 59–60
  observations in, 167
  overview of, 474–477
  patient interview and limitations from, 128
  process measures and, 279–280s
AD. See Alzheimer’s disease (AD)
AD8 Dementia Screening Interview, 229
ADA. See Americans with Disabilities Act (1990)
Adaptive treatment. See Accommodations; Compensatory strategies; Modifications; Restorative versus adaptive treatment
ADD. See Auditory Discrimination in Depth (ADD)
Adolescents. See also Children, 150, 182–183, 198, 206, 209, 259, 262

Advocacy
- in assessment procedures, 116, 122
- for referrals and services, 123–124, 149, 299–300, 423s, 490
- for self, 379
- for treatment intensity, 355
- for use of AAC, 422–423

Affect Balance Scale (ABS), 290–291

Affordable Care Act (2010), 482

A-FROM. See Living With Aphasia: Framework for Outcome Measurement (A-FROM)

Age
- as a testing confound, 214
- as prognostic factor, 216, 217, 267–268
- Ageism, 217
- Aging population, differential diagnostic difficulties in, 112

Agitation. See Disruptive behaviors

Agonists, 397

Agrammatism, 37, 38, 39, 335, 337, 338

Agraphia, 41, 42, 51

Agraphia treatment. See Orthographic treatment approaches

AIDS, 93

Akinetopsia, 152

ALA. See Assessment for Living With Aphasia (ALA)

Alcohol abuse, 110, 111

Alexia, 40–41, 42, 51

Alexia treatment. See Orthographic treatment approaches

ALFA. See Assessment of Language-Related Functional Activities (ALFA)

Allesthesia, 57–58

Allographic conversion deficits, 309

AllTalk, 421

Alphabet search, 369

Alzheimer’s disease (AD). See also Dementia
- angular gyrus syndrome versus, 111
- causes of, 103–105
- complicating conditions in, 152, 157, 159
- diagnosing, 103, 104, 112
- lesion location for, 73
- perceptual deficits in, 73
- Pick’s disease versus, 105
- PPA and, 52
- prevalence of, 102
- prognostic factors in, 270
- pseudodementia versus, 112
- quality-of-life measures for, 293
- risk and protective factors for, 102, 103
- symptoms of, 22, 74, 75–76, 219

Alzheimer’s Disease Caregiver’s Questionnaire, 232

Alzheimer’s disease tests, 184, 206, 208, 212, 232

Alzheimer’s disease treatment. See also Behavioral approaches for cognitive disorders
CAM, 458, 460, 462, 463, 464
memory treatment, 373, 374
pharmacotherapy approaches, 399–400, 405, 406, 407, 408

taped autobiographical narratives, 368

Alzheimer’s Quick Test, 232–233

Amantadine, 399, 405

American Heart Association, 36

American Sign Language (ASL), 416

American Speech–Hearing Association (ASHA)

  on advocacy, 490
  on documentation, 488
  on EBP, 10–11
  ICF and, 2
  on practice economics, 487
  on prevention activities, 470
  program evaluations by, 281, 282
  quality-of-life measures by, 293
  on SLPAs, 487
  support organization resources, 456

Americans With Disabilities Act (1990), 448, 482

Amer-Ind signs, 213, 416–417

Amnesia. See Post-traumatic amnesia (PTA)

Amphetamines, 399–400, 401–402

Amusia, 150

Aneurysms, 88, 88f

Angular gyrus, 29

Angular gyrus syndrome, 111

Anomia, 38–40, 41, 71

Anomia treatment, 391

Anomic aphasia, 48, 50, 51, 221

Anosodiaphoria, 59

Anosognosia

  assessments for, 264–265
  definition of, 59
  in frontotemporal dementia, 75
  functional outcomes of, 226
  as prognostic factor, 222, 270
  in TBI, 228

Antagonists, 397

Anterograde amnesia, 69–70

Anterograde memories, 22, 31

Anticipatory awareness deficit, 70

Antipsychotic medications, 400, 407–408

Anxiety, 220

Aphasia

  A-FROM and, 275
  apraxia of speech versus, 153–154
  classification systems for, 46–47, 48, 49–52, 179
  complicating conditions after, 150, 153
  contextual variability of, 133
  definition and prevalence of, 36, 49, 50, 51
  explanations of, 45–46
frontotemporal dementia and, 63–64
patient interview and limitations from, 128
prognostic factors in, 219, 220–221
psychiatric disorders screenings and, 160
symptoms of, 36–45
types of, 50–52, 53
Aphasia groups, 437
Aphasia screenings, 172t, 173
Aphasia tests. See also Lexical–semantic processing tests; Morphosyntactic processing tests; Orthographic processing tests; Phonological processing tests; specific tests
dementia patients and use of, 183–184
overview of, 175–179, 185, 191, 198, 212
RHD tests versus, 180
TBI tests versus, 183
Aphasia treatment. See also Lexical–semantic treatment approaches; Morphosyntactic treatment approaches; Orthographic treatment approaches; Phonological treatment approaches
AAC considerations in, 419–420, 421–422
Amer-Ind signs, 417
APT, 364, 390
CAM, 458, 461–462, 464
in groups, 437
PACE, 432–434
pharmacotherapy approaches, 399–400t, 401–403, 408
SCA, 443–444
sentence repetition tasks, 390
variables for consideration in, 37
Applications (Apps). See also Software and applications, as treatment activities, 421–422
Apraxia Battery for Adults–Second Edition, 153, 157, 213
Apraxia of speech, 128, 153–154
APT. See Attention Process Training (APT)
Arcuate fasciculus, 29
Arizona Battery for Communication Disorders of Dementia (ABCD), 176t, 184
Arteriovenous malformation (AVM), 88–89
ASHA. See American Speech-Hearing Association (ASHA)
ASHA Functional Assessment of Communication Skills for Adults (ASHA FACS), 281, 283, 285
ASHA QCL. See Quality of Communication Life Scale (ASHA QCL)
ASL. See American Sign Language (ASL)
Assessment confounds. See Complicating conditions
Assessment for Living With Aphasia (ALA), 295, 296f
Assessment of Communicative Effectiveness in Severe Aphasia, 176t, 178
Assessment of Intelligibility of Dysarthric Speech, 154
Assessment of Language-Related Functional Activities (ALFA), 176t, 284–285
Assessment of Nonverbal Communication, 213
Assessment procedures, 124–144, 166, 171–174
Assessments. See also Cognitive disorders assessment of body structure and function; Linguistic disorders assessment of body structure and function; specific tests
in acute care, 473, 475–476
approach considerations for, 119–123
goals of, 116, 117–119, 121s
non-standardized procedures in, 476s
in outpatient settings, 480
in rehabilitation phase, 478
reimbursement issues with, 116s
sharing results of, 144–145
Assessments of activity, participation, and quality of life
approach considerations for, 278–279
authentic assessment and ethnography, 295, 297–298
environmental factors and, 448
functional measures for, 279–286
importance of, 273–274, 288–289
list of measures by population, 276–277t
participation measures, 286–288
quality-of-life measures, 289–294
relationship among measures, 294–295, 296f
term definitions in, 274–275
Association areas and fibers, 29
Ataxia, 158
Attention, 19–20, 30–31
Attention deficits
with aphasia, 43
in dementia, 74
in RHD, 54, 56–58, 60, 62
in TBI, 68–69
Attention Process Training (APT), 363, 364
Attention Process Training–II (APT-II), 363, 364, 366, 390
Attention Process Training–III (APT-III), 363, 364, 364t, 366
Attention switching, 20, 20r, 31
Attention tests, 233, 239–240, 248–252
Attention treatment. See also Intention treatment
attention training or retraining, 360, 363–365, 390
cognitive strategies, 424
combined approaches, 366–367
for neglect, 358–363
strategy training, 365
Audiologists, 148, 150, 449
Audiology, 120r
Audio recordings, 368, 378, 380
Auditory agnosias, 55t, 73–74, 150
Auditory Discrimination in Depth (ADD), 304t
Auditory perceptual deficits screenings, 150, 151t
Auditory phonological analysis, 15, 16f
Auditory sound agnosia, 150
Auditory-verbal working memory tests, 253–254
Auditory word-picture matching, 302
Augmentative or alternative communication (AAC). See also External devices, 418–422
Authentic assessment and ethnography, 295, 297–298
Authentic context, 454
Autobiographical memory. See also Episodic memory, 58
Autopagnosia, 152
AVM. See arteriovenous malformation (AVM)
Awareness training, 377–378, 379t, 380
Axonal shearing, 98, 99f

B
Back to the Drawing Board, 413
Backward chaining, 373
Bacterial meningitis, 92
BADS. See Behavioral Assessment of Dysexecutive Syndrome (BADS)
Balanced Budget Act of 1997, 484
Balloons Test, 250, 251
Barkley Deficits in Executive Functioning Scale (BDEFS), 243
Barotraumas. See Blast injuries
Barrier games, 345–346, 433
BASA. See Boston Assessment of Severe Aphasia (BASA)
Basal ganglia, 29, 30f, 31, 33, 83
Basement effect, 239
BAT. See Bilingual Aphasia Test (BAT)
BDAE. See Boston Diagnostic Aphasia Examination (BDAE)
BDAE-3. See Boston Diagnostic Aphasia Examination–Third Edition (BDAE-3)
BDEFS. See Barkley Deficits in Executive Functioning Scale (BDEFS)
BEAC. See Behavior, Emotion, Attitude, and Communication questionnaire (BEAC)
BEDS. See Behavioral Evaluation of Deficits in Executive Functioning Scale (BDEFS)
Behavioral approaches for cognitive disorders, 357–392
Behavioral approaches for linguistic disorders, 299–355
Behavioral Assessment of Dysexecutive Syndrome (BADS), 229, 242
Behavioral Inattention Test (BIT), 251
Behavior Rating Inventory of Executive Function–Adult Version (BRIEF-A), 243
Benign brain tumors, 91
BEST-2. See Bedside Evaluation Screening Test of Aphasia–Second Edition (BEST-2)
Bifemelane hydrochloride, 399t, 402
Bilingual aphasia, 51–52
Bilingual Aphasia Test (BAT), 176t, 178
Bilingualism, 338–339s
Bilingual speakers. See also specific types of speakers, 125, 142–143s, 173, 178
Biofeedback, 458
Biographical factors, in prognosis, 217–218, 267–268
BIT. See Behavioral Inattention Test (BIT)
Blast injuries, 96–97, 100, 148, 152
Blood clots, 88, 97, 98t
Blood supply, in brain, 80–84
BNT. See Boston Naming Test (BNT)
Board games, 350
Body structure and body function, 2, 5
Books, 467t
BOSS. See Burden of Stroke Scale (BOSS)
Boston Assessment of Severe Aphasia (BASA), 176t, 178, 179
Boston Diagnostic Aphasia Examination (BDAE), 183, 381
Boston Diagnostic Aphasia Examination–Third Edition (BDAE-3), 47, 173, 176t, 177–178, 203
Boston Naming Test (BNT), 121s, 138, 197

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Boston Naming Test—Second Edition, 178
Bradykinesia, 158
Brain. See Blood supply, in brain; Neuroanatomy
Brain abcesses, 92–93
Brain attacks. See also Strokes, 89
Brain-behavior relationships, 25–27s
Brain damage. See Primary brain damage; Secondary brain damage; specific conditions
Brain stimulation approaches, 331–332
Brain tumors, 90–92, 113, 219, 374
BRIEF-A. See Behavior Rating Inventory of Executive Function—Adult Version (BRIEF-A)
Brief Test of Head Injury (BTHI), 176t, 182
Broca’s aphasia. See also Expressive aphasia, 48t, 49, 221, 338, 464
Broca’s area, 28, 29s, 31, 83
Bromocriptine, 399t, 401
BTHI. See Brief Test of Head Injury (BTHI)
Bubble maps. See Metaphor Training Program (MTP)
Burden of Stroke Scale (BOSS), 292
Burns Brief Inventory of Communication and Cognition, 176t, 180–181

C
Calibrated Ideational Fluency Assessment (CIFA), 264
California Verbal Learning Test—Second Edition (CVLT-2). See also Rey’s Visual Design Learning
Test (RVDT), 252–253
CAM. See Complementary and alternative medicine (CAM)
Cambridge Prospective Memory Test, 255
Cancellation tasks, 249, 251, 360, 362
Canonical word order, 18, 203
Cantonese speakers, 197
Capitation systems, 485
Caps or limits, 484, 486
Caregiver-Administered Communication Inventory, 167
Caregiver assessments, 143–144
Caregiver attitudes, 216t, 218, 460
Caregiver burden, 143, 226
Caregiver education. See also Counseling and education; Family education
assessment results sharing and, 145
communication partner training, 210, 415, 440–448, 454
on environmental modifications, 448–451
on external devices use, 427, 431–432
in home health care, 480
on memory books, 428–430
prognosis and, 219
relaxation therapy and, 459
on spaced retrieval, 371
on strategies, 431–432
on topic coherence and cohesion treatment, 347
on treatment purposes, 301s, 354
Caregivers. See also Families
case history input of, 228
functional measures and, 284
observations of interactions with, 167
quality-of-life measures for, 293
screening input of, 174, 229, 232
workbooks and software use as respite for, 352
Caregiver strategies, negative, 133, 144, 167
CARF. See Commission on Accreditation of Rehabilitation Facilities (CARF)
Carotid arterial system, 80–81, 82f, 83, 84
CART. See Copy and Recall Treatment (CART)
Case histories, 124–126, 167, 168–170f, 228–229
Case-mix adjustment, 486
Case rate systems, 485, 486
CATE. See Complexity Account of Treatment Efficacy (CATE)
Catecholamine system, 398, 401–402, 404–405

Category Test, 260
Caudate nucleus, 30f, 31, 33, 109
CC. See Coarse coding (CC)
CDP. See Communicative Drawing Program (CDP)
CELF-5. See Clinical Evaluation of Language Fundamentals–Fifth Edition (CELF-5)
Cell phones. See iPhones; Smartphones
Centers for Disease Control and Prevention (CDC), 94
Centers for Medicare and Medicaid Services (CMS), 283, 482, 486
Cerebellum, 31, 32f, 33
Cerebral arteries. See Cerebral vascular system
Cerebral hemispheres. See also Left hemisphere; Neuroanatomy; Right hemisphere, 81, 82f
Cerebral vascular system, 80–84
Cerebrovascular accidents. See Strokes
CETI. See Communicative Effectiveness Index (CETI)
Chaining techniques. See also Cueing hierarchies, 373–374, 375
CHART. See Craig Handicap Assessment and Reporting Technique (CHART)
Chemosensory impairments, 149–150
Children. See also Adolescents
stroke incidence in, 85
TBI incidence and, 94, 95
tests for, 182–183, 208–209, 258, 262
tumor incidence in, 91
Chinese speakers, 60, 178, 197, 265
Cholinergic system, 402–403, 406
CIAT. See Constraint-induced aphasia therapy (CIAT)
CIFA. See Calibrated Ideational Fluency Assessment (CIFA)
Cingulate gyrus, 31, 32f
Circle of Willis, 83–84, 89
Circumlocutions, 37, 39, 40t, 200
CIUs. See Correct information units (CIUs)
Classical conditioning, 21f, 22
Clinical competency
to advocate for referrals, 299–300
on formal test utility, 135, 136, 138–139, 140–141, 175, 184, 190
on range of communication, 349–350s
on workbook and software use, 353

Clinical Evaluation of Language Fundamentals–Fifth Edition (CELF-5), 182
Clinical reasoning, 7, 11, 476
Clinician-developed probe tasks, 171–172, 208, 209, 210, 213–214
Clinician Interview-Based Impression of Change—Plus Caregiver Information (CIBIC+), 132
Clock Drawing, 233
Closed class words, 202
Closed head injuries. See also Traumatic brain injuries (TBI), 96, 97–98, 99f
CLQT. See Cognitive Linguistic Quick Test (CLQT)
CMS. See Centers for Medicare and Medicaid Services (CMS)
Coarse coding (CC). See also Contextual Constraint Treatment, 341
Cocaine abuse. See Substance abuse
Cognistat, 173
Cognitive Change Checklist, 232
Cognitive-communicative disorders. See also specific disorders, 53–54, 71, 227s
Cognitive-communicative disorders tests. See also specific tests, 140–141, 176–177t, 185
Cognitive disorders. See also specific disorders, 8t, 111–113
Cognitive disorders assessment of body structure and function. See also specific tests, 225–270
Cognitive disorders treatment. See Activity-focused treatment; Behavioral approaches for cognitive disorders; Participation-focused treatment; Pharmacotherapy approaches
Cognitive flexibility, 24, 32, 45
Cognitive flexibility tests, 258, 262
Cognitive functioning, general, tests for, 235, 236–237t, 238–239
Cognitive inflexibility, 75
Cognitive Linguistic Quick Test (CLQT), 258, 265
Cognitive neuropsychological approaches, 300–301, 322–330
Cognitive outcomes and prognosis, 221–222
Cognitive processing, 14, 18–24, 30–33, 42–45, 270
Cognitive stimulation general approaches, 386–387
Cognitive strategies, compensatory, 423–425
Cognitive treatment, 390–392
Cohesion analyses, 210–213
Color Trails Test, 248, 249
Coma, 65
Combine approaches, in attention remediation, 366
Combined semantic and phonological treatment approaches, 330–331
Commission on Accreditation of Rehabilitation Facilities (CARF), 122
Common Objects Memory Test, 265
Communication, 13–14
Communication approaches, multimodality, 413–418
Communication books. See Memory books
Communication partners. See also Caregivers; Families
AAC and, 418
in barrier games, 345–346
discourse sampling and, 210
memory books and, 430
in topic coherence and cohesion treatment, 347
training of, 415, 440–448, 454
Communication symptoms. See also Aphasia, 59–63, 75–76, 216t, 219–220
Communication systems, in ICUs, 473–474
Communicative Drawing Program (CDP), 413–414

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Communicative Effectiveness Index (CETI), 132, 284
Communicative Participation Item Bank, 287–288
Communicative Profiling System (CPS), 295, 297
Community-based teams, 123
Community Integration Questionnaire (CIQ), 286–287
Community resources, 455–457
Compensatory strategies. See also Accommodations; Modifications
  for activity-focused treatment, 412–434
  for allographic conversion deficits, 309
  group treatment and, 438
  lighthouse imagery strategy, 361
  metacognitive training, 358
  mnemonic strategies, 368–369
  practice of, 430–434
  strategy training, 365, 368–370
  for writing deficits, 311
Competency. See Clinical competency
Complementary and alternative medicine (CAM), 457–464
Complex Figure Test, 256
Complexity Account of Treatment Efficacy (CATE), 337
Complicating conditions
  observations of, 134
  overview of, 147–164
  as prognostic factors, 216t, 220, 222, 268–269
  sensitivity to, 229
Comprehension deficits
  in aphasia, 37–38, 46–47
  figurative language approaches for, 342–344
  linguistic stimulation approaches for, 310–313
  phonological treatment approaches for, 329
  semantic treatment approaches for, 323–324
  suprasegmental impairments treatment for, 304–305
Comprehensive Aphasia Test, 176t
Comprehensive Apraxia Test, 153
Comprehensive Receptive and Expressive Vocabulary Test–Third Edition (CREVT-III), 198, 204
Comprehensive Test of Nonverbal Intelligence–Second Edition (CTONI-2), 262, 265
Comprehensive Trail-Making Test, 248
Computer-Assisted Visual Communication system (C-VIC), 420
Computerized tomography (CT scans), 26s
Computers. See Software and applications, as treatment activities
Conduction aphasia, 48t, 50, 221
Confabulation, 61
Confidentiality, 482
Congruent overlap, 441
Conjunctive devices, 211
Connectionist classification systems, 47, 48t, 49–50
Conners’ Continuous Performance Test III, 248
Consciousness disorders, 65–67
Constraint-induced aphasia therapy (CIAT), 355
Construct validity, 136t, 137
Content validity, 136–137
Contextual Constraint Treatment, 342, 343f
Contextual factors. See also Environmental factors
  aphasia and, 37, 45
  attention deficits and, 62
  definitions of, 4
  generalization and, 354
  in home health care, 480
  in LTC settings, 479
  pragmatics and discourse impairments treatment and, 348–349
  pragmatics and discourse processing and, 60–61, 340, 341
Continuous quality improvement. See Program evaluations
Continuous Visual Memory Test (CVMT), 257
Continuum of care, 470–481
Contrastive stress procedures, 305, 306t
Controlled Oral Word Association Test, 263
Conversation, CIUs and, 199
Conversational rules, 18
Conversational script training, 322, 454
Conversational skills treatment, 347–348
Conversation Analysis Profile for People With Aphasia, 167
Conversation Analysis Profile for People With Cognitive Impairment, 167
Conversation partners. See Communication partners
Cooking tasks, 242–243
Cooling therapy, 90
Coping style, as prognostic factor, 269
Coping With Aphasia, 466
Copy and Recall Treatment (CART), 313–314
Copying tasks, 309–310
Correct/incorrect judgments, 302
Correct information units (CIUs), 199
Cortical dementia. See also Dementia, 73s
Cortical stimulation, 26s
Cost effectiveness. See Health-care economics
Counseling and education. See also Caregiver education; Family education; Patient education, 464–465, 467t, 468
Coup and contrecoup injuries, 97–98, 99f
Craig Handicap Assessment and Reporting Technique (CHART), 286–287
CREVT-III. See Comprehensive Receptive and Expressive Vocabulary Test–Third Edition (CREVT-III)
Criterion-Oriented Test of Attention, 248
Criterion-related validity, 137
Critical appraisals, 9, 10, 11
Critical care units. See Intensive care units (ICUs)
Critical thinking. See also Clinical reasoning, 7, 11, 476
Crossed aphasia, 51
CTONI-2. See Comprehensive Test of Nonverbal Intelligence–Second Edition (CTONI-2)
CT scans. See Computerized tomography (CT scans)
Cueing approaches, in neglect treatment, 360–363
Cueing hierarchies. See also Chaining techniques, 314, 315t, 316–317
Cultural variables. See Ethnocultural variables
C-VIC. See Computer-Assisted Visual Communication system (C-VIC)
From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
CVMT. See Continuous Visual Memory Test (CVMT)
Czech speakers. See also Non-English speakers, 173

D
Daily Mishaps Test, 214
Dartmouth COOP Functional Assessment Charts, 290
Databases, 7, 8t
DCT. See Discourse Comprehension Test (DCT)
Deblocking activities. See also Speech perception tasks, 310–311
Declarative memory, 20, 21f, 22, 31
Delis-Kaplan Executive Function System (D-KEFS), 207, 239, 241–242
Dementia. See also Progressive neurological diseases; specific conditions
  AIDS and HIV and, 93
  chemosensory impairments and, 149–150
  complicating conditions in, 152, 154
  functional outcomes of, 74, 76
  inappropriate assessment of, 227s, 234s
  overview of, 72, 73s
  patient interview and limitations from, 128
  prognostic factors in, 219
  psychiatric disorders screenings an, 160
  quality-of-life measures for, 293
  symptoms of, 73–76
Dementia Outcomes Measurement Suite (DOMS), 293
Dementia Quality of Life Questionnaire (DQOL), 293
Dementia Rating Scale–Second Edition, 232, 262
Dementia tests, 176–177t, 183–185, 232, 233, 239, 262
Dementia treatment. See also Behavioral approaches for cognitive disorders
  CAM, 458, 460, 463–464
  communication partner training, 444–445
  general cognitive stimulation approaches, 386
  in groups, 438–439
  lack of referrals for, 299–300
  memory treatment, 371, 374
  pharmacotherapy approaches, 399t, 402, 408
  reality orientation to environment, 449–450
  social conventions treatment, 348
Dementia with Lewy bodies. See also Dementia, 74, 158, 212, 219, 399t, 406
DEMQOL, 293
Depression
  caregiving consequences and, 143
  as a complicating condition, 158–159
  as prognostic factor, 220
  pseudodementia and, 112
  SSRIs and, 408
  tests for, 206
Derivational morphemes, 18, 202
Diabetes, as prognostic factor, 268t, 269
Diagnosis-related groups (DRGs), 486
Diagnostic questions, 9s
Diagnostic reports, 144–145
Dichotomous classification systems, 46–47
Differential diagnosis, 472, 473, 475, 476
Disability, 3
Discharge recommendations, 476–477, 478
Discounted fee-for-service model, 484
*Discourse Comprehension Test* (DCT), 206
Discourse genres, 209–210, 212–213
Discourse informativeness, 61, 71, 199
Discourse interpretations, 62
Discourse macrostructure, 61, 71
Discourse processing. See Pragmatics and discourse processing
Discourse samples, 191, 199, 204–205, 209–213
Disinhibition, 75, 158, 382–383
Disjunct markers, 441
Disruptive behaviors. See also Complicating conditions, 440, 445, 450, 459, 460
Divided attention, 20, 249
Documentation. See also Diagnostic reports, 488
DOMS. See Dementia Outcomes Measurement Suite (DOMS)
Donepezil, 399t, 403, 406, 407
Dopamine. See also Catecholamine system, 397–398
DQOL. See Dementia Quality of Life Questionnaire (DQOL)
Drawings, 57f, 214, 233, 250, 413–416
DRGs. See Diagnosis-related groups (DRGs)
Drug treatments. See Pharmacotherapy approaches
Dual coding, 369
Dysarthria, 128, 154, 155t, 156, 156s
*Dysarthria Examination Battery*, 154
Dysphagia treatment. See also Swallowing function and services, 487, 490s

**E**
Ecological validity, 137, 392
Economics. See Health-care economics
Edema, in the brain, 100
Education. See Caregiver education; Counseling and education; Family education; Team education
Education, as a testing confound, 214–215, 229
Education, as prognostic factor, 268
EEG. See Electroencephalography (EEG)
Efficacy. See Treatment efficacy
Effortful learning, 374, 375
Egocentric output, 61
Elder Rehab program, 463
Electroencephalography (EEG), 27s
Electronic indexes, 7, 8t
Ellipsis, 211
Embolic stroke, 86–87
Embolus, 86
Emotion perception deficits and treatment, 349
“Empty speech,” 38
Encoding, 21f, 23–24, 31

*From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,* by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Encoding deficits, 58, 69–70
Endarterectomy, 87
Energent awareness deficit, 70
Environmental adaptation approaches, 376–377
Environmental agnosia, 152
Environmental factors. See also Contextual factors
  acoustics, 448–449
  definition of, 4
  formal tests and effects of, 134
  hidden deficits due to, 59–60, 123, 228, 266
  ICF assessment goals and, 118, 122
  modifications to, 448–451
  MS and, 109
  neglect syndrome and, 249
  observations and, 133, 285
  Parkinson’s disease and, 107
  pragmatics and discourse processing and, 341, 348–349
  principles for organizing, 450–451
  psychiatric disorders and, 159
  screenings and, 174s
  TBI attention deficits and, 68
  variability in aphasia symptoms across, 133
Episodic memory, 21–22, 31, 69
Error analyses, 199–201, 204–205
Errorless learning, 373, 374–375, 391, 432
Ethics. See also Clinical reasoning, 116s
Ethnic differences. See also Ethnocultural variables; Racial differences, 85, 102
Ethnocultural variables. See also Authentic assessment and ethnography
  AAC and, 420
  in assessments, 139s, 142–143s
  generalization and, 354
  pragmatics and discourse processing and, 340
  as a testing confound, 215, 229
  in tests, 178
Event Drawing Task, 214
Evidence-based practice (EBP). See also Functional outcomes, 6–13, 490
Examining for Aphasia–Fourth Edition, 176t
Executive functioning, 24, 32–33, 222, 270, 369
Executive functioning deficits, 44–45, 59, 70–71, 75
Executive functioning screenings, 229
Executive Function Route-Finding Task, 259
Executive function treatment, 376–378, 379t, 380–386
Exercise, 462–465
Expanded Trail Making Test, 248, 249
Expression deficits. See Production deficits
Expressive aphasia. See also Broca’s aphasia, 46–47
Expressive Vocabulary Test–Second Edition, 198
External devices. See also Augmentative or alternative communication (AAC); Memory aids,
  413–418, 425, 426t, 427–432

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
F
Facebook, 443s
“Face-saving” repair strategies, 442–443
Falls, 95
False starts, 200, 200t
Families. See also Caregivers, 122, 164s, 210
Family attitudes. See also Caregiver attitudes, 216t, 218
Family education. See also Caregiver education; Counseling and education
   in acute care, 477
   HIPPA and, 482
   in ICUs, 474
   lighthouse imagery strategy, 361
   prognosis and, 219
   in SNFs, 478–479
FAS test, 263
FAVRES. See Functional Assessment of Verbal Reasoning and Executive Strategies (FAVRES)
FCMs. See Functional Communication Measures (FCMs)
FCP. See Functional Communication Profile (FCP)
FDA-2. See Frenchay Dysarthria Assessment—Second Edition (FDA-2)
Fee-for-service model, 483–484
Figurative language, 60, 71, 76, 446t
Figurative language and alternative meanings treatment, 341–345
Fillers, 200
FIM. See Functional Independence Measure (FIM)
FLCI. See Functional Linguistic Communication Inventory (FLCI)
Floor effect, 239
Florida Affect Battery, 192
FLS. See Functional Life Scale (FLS)
Fluency. See Speech fluency
Fluency tests, 263
Fluent aphasia, 46, 47
Fluvoxamine, 400t, 408
FMRI. See Functional magnetic resonance imaging (fMRI)
Focused attention, 20, 20t, 62
Focused attention tests, 248–249
Formal test procedures, 134–143
Fornix, 32t
Forward chaining, 373–374
Frenchay Dysarthria Assessment—Second Edition (FDA-2), 154
French speakers, 239, 243
Frontal Assessment Battery, 232
Frontal lobe lesions, tests for, 207
Frontal lobes
   blood supply for, 81, 82f
   Coup and contrecoup injuries in, 98
   dopamine and, 401
   functions of, 28f, 31, 32–33
   Korsakoff’s disease and, 110
Frontotemporal dementia. See also Dementia
   aphasia and, 63–64s, 202

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Index

diagnosing, 106–107
pharmacotherapeutic approaches for, 399, 406, 408
prognostic factors in, 270
symptoms of, 73–74, 75, 76, 219
tests for, 208, 212
Frontotemporal lobar degeneration (FTLD)
complicating conditions in, 158, 159
definition and overview of, 105–107
PPA and, 52
screenings for, 173
tests for, 184, 232
Functional Assessment of Verbal Reasoning and Executive Strategies (FAVRES), 259
Functional communication. See Assessments of activity, participation, and quality of life
Functional Communication Measures (FCMs), 281, 282, 283, 286
Functional Communication Profile (FCP), 283–284
Functional deficits, 488
Functional Independence Measure (FIM). See also ASHA Functional Assessment of
Communication Skills for Adults (ASHA FACS), 280, 285
Functional Life Scale (FLS), 287
Functional Linguistic Communication Inventory (FLCI), 176, 184
Functional magnetic resonance imaging (fMRI), 27s
Functional measures, 274–275, 279–286
Functional outcomes. See also Cognitive outcomes and prognosis; Linguistic outcomes and
prognosis; specific cognitive-communication disorder
amnesia and, 67, 69
anosognosia and, 59, 226
blast injuries and, 97
CAM and, 460, 461–462, 463, 464
caregiver assessment and, 143
complicating conditions and, 134
external devices and, 427
group treatment and, 434
ICF assessment goals and, 118
limb apraxia and, 157
making assumptions about, 118–119
of memory books, 430
neglect and, 43, 56, 226
psychiatric disorders and, 159
thorough assessments and, 116
vegetative state and, 66
vocation and, 226
Functional tasks integration, for generalization, 366
Functional tests, 242–243, 252, 262–263
Funding agencies. See also Health-care funding models; Medicaid; Medicare; Private insurers;
Third-party payers, 355

G
Galantamine, 400, 402, 406
Gaming platforms, 388
GCS. See Glasgow Coma Scale (GCS)

Gender differences
- Alzheimer’s disease and, 102
- FTLD and, 105
- meningiomas and, 91
- MS and, 109
- Parkinson’s disease and, 107
- Pick’s disease and, 105
- as prognostic factors, 216t, 217–218, 268
- strokes and, 85
- TBI and, 95

General cognitive functioning tests, 235, 236–237t, 238–239

Generalization
- of attention treatment, 364–365
- of computer-assisted therapy programs, 353
- external devices and, 427
- factors to encourage, 354–355, 392, 431–432
- of general cognitive stimulation approaches, 387
- of linguistic stimulation treatment, 317, 319, 321, 322
- of morphosyntactic treatment, 334, 336, 338, 342, 344
- of neglect treatment, 360, 361
- of phonological treatment, 307
- of semantic treatment, 323, 326, 328

Genres. See Discourse genres

Geographic differences, 85, 109, 123s
- German speakers, 243
- Gestures, 41, 213, 416–418
- GI. See Guided imagery (GI)
- GIST. See Group Interactive Structure Treatment (GIST)
- Glasgow Coma Scale (GCS), 65
- Glioblastomas, 91
- Global aphasia, 48t, 49, 221
- Goal Management Training (GMT), 384, 385f
- Goal setting, planning, and problem-solving impairments treatment, 383–386
- GORT-5. See Gray Oral Reading Tests–Fifth Edition (GORT-5)
- Graphemes, 17
- Graphemic processing. See Orthographic processing
- Graphic displays. See Metaphor Training Program (MTP)
- Gray Oral Reading Tests–Fifth Edition (GORT-5), 207
- Greek speakers, 197, 292
- Group Interactive Structure Treatment (GIST), 350
- Group treatment
  - awareness training, 380
  - as compensatory strategy, 415f, 416
  - conversational skills and, 347
  - in LTC settings, 479
  - overview of, 434–439
    - social conventions treatment and, 348, 349, 350
- Guided imagery (GI), 458
H
HAND (HIV-associated neurocognitive disorders), 93
Handicap, 3
HD. See Huntington’s disease (HD)
Health-care delivery models. See Continuum of care
Health-care economics, 476, 483–490
Health-care funding models, 483–486
Health-care providers. See also specific professionals, 447–448, 449, 474, 477, 478–479, 489–490
Health-care reform. See Patient Protection and Affordable Care Act (2010)
Health-care settings. See also specific levels of care, 116, 116s, 117, 123
Health Insurance Portability and Accountability Act (HIPAA 1996), 482
Health literacy, 145, 160
Hearing loss. See also Acoustic environment, 148
Hearing screenings, 148
Helm Elicited Program for Syntax Stimulation (HELPSS), 333–335
HELPSS. See Helm Elicited Program for Syntax Stimulation (HELPSS)
Hematomas, 88, 97, 98t
Hemiatkinesia, 57
Hemianesthesia, 149
Hemianopsia, 149
Hemi-inattention. See also Neglect syndrome, 56–57
Hemiparesis, 156
Hemiplegia, 156
Hemispatial neglect. See also Neglect syndrome, 56–57
Hemispatial patching or sunglasses, 359
Hemorrhagic strokes, 86, 88–89
HHRGs. See Home health resource groups (HHRGs)
Hierarchy for cueing. See Cueing hierarchies
Hierarchy of evidence, 6
Hierarchy of pre-stimulation cues. See Contextual Constraint Treatment
Hierarchy of syntactic constructions. See Helm Elicited Program for Syntax Stimulation (HELPSS)
Higher-level language processes. See also Pragmatics and discourse processing, 180
HIPAA. See Health Insurance Portability and Accountability Act (HIPAA 1996)
Hippocampus, 31
HIV, 93
Holistic treatment. See Complementary and alternative medicine (CAM)
Home health care, 118, 479–480
Home health resource groups (HHRGs), 486
Homonymous hemianopsia, 149
Hopkins Verbal Learning Test–Revised, 252
Hospitals. See Health care settings; specific levels of care
Human immunodeficiency virus (HIV), 93
Humor appreciation, 60, 350
Huntington’s disease (HD)
complicating conditions in, 157, 158
lesion location for, 73s
overview of, 108–109, 219
pharmacotherapy approaches for, 400t, 405, 406

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
sensory stimulation and, 460
tests for, 196, 206
Hypoxic-ischemic brain injuries, 100, 101

ICD-50. See Sony IC Recorder (ICD-50)
ICF. See International Classification of Functioning, Disability, and Health (ICF)
ICIDH. See International Classification of Impairment, Disability, and Handicap (ICIDH)
Iconic gestures, 213
ICUs. See Intensive care units (ICUs)
Ideational apraxia, 157
Identification cards, 422
Ideomotor apraxia, 157
Illogical verbal output, 54
Imagery. See Guided imagery (GI); Lighthouse imagery strategy; Visual imagery
Impairment, 3
Impulsivity. See Disinhibition
Incentives, therapy, 487
Indefinite substitutions, 39, 40, 200
Infarcts, 86
Infections, 92–94, 100, 113
Inferencing, 61, 63, 347
Inflectional morphemes, 18, 202
Informativeness. See Discourse informativeness
Inhibition, 23, 24, 32, 45, 258, 261–262
Initiation, 32, 75
In-network providers, 484–485
Inpatient rehabilitation, 477–478
Insurance agencies. See Private insurers
Intake form, 168–170
Intellectual awareness deficit, 70
Intelligence. See Premorbid intelligence
Intensive care units (ICUs), 472–474
Intention treatment, 392
Interaction, 454
Internal capsule, 29, 30, 83
International Classification of Functioning, Disability, and Health (ICF)
assessment goals in, 117, 118, 122, 133, 144
assessments of activity, participation, and quality of life and, 274–275
CAM and, 457
EBP applied to, 11, 13
overview of, 2–6
International Classification of Impairment, Disability, and Handicap (ICIDH), 2
Interpreters, 142–143
Inter-rater reliability, 135, 136
Intervention. See specific approaches or treatments
Interview formats, 132–133
Intracranial pressure, 100
iPads, 420, 421
iPhones, 421
Irreversible dementia. See also Vascular dementia, 107, 110, 112
Ischemic strokes. See also Strokes, 86–87, 89–90
Isolation aphasia. See Transcortical aphasia
Italian speakers, 292

J
Jargon, 37, 39
Joint Commission of Accreditation of Healthcare Organizations (JCAHO), 122

K
Keywords, 308–309
Kindle Fires, 420
Knowledge base. See Declarative memory
Korean speakers, 243
Korsakoff’s disease, 110, 373

L
Labeling behavior, 199
Lability, 67, 158
Lacunar stroke, 86
Language. See also Bilingualism; Bilingual speakers; Linguistic processing, 14, 28–29, 30f
Language disorders. See also specific conditions, 8t, 111–113
“Language neurotransmitter,” 397–398s
Language sampling. See also Discourse samples, 198–201, 209–213
Language Screening Test, 172
La Trobe Communication Questionnaire, 167, 174, 286
Learning. See Encoding
Left frontal lobe, 28, 31
Left hemisphere, 28–29, 56, 401
Left hemisphere disorders. See also Aphasia; Right-sided neglect
ASHA FACS and, 281
assessment goals in, 117t, 119
complicating conditions after, 150, 153, 156–157
prognostic factors in, 269–270
Left parietal lobe, 29
Left prefrontal cortex, 31
Left-sided neglect. See also Neglect syndrome, 68
Legibility. See also Spelling deficits treatment, 41
Legislation, 481–482, 486–490
Lesion locations
assessment goals and, 117t, 119, 165–166
as prognostic factors, 216b, 218–219, 222, 269–270
Lesion method, 26s
Letter-to-sound rules, 16f, 17
Levels-of-evidence rating scales, 10
Levodopa, 399t, 401
Lewy body dementia. See Dementia with Lewy bodies
Lexical ambiguity resolution, 61
Lexical markers, 211

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Lexical Orthographic Familiarity Test, 218
Lexical–semantic processing, 16f, 17, 41, 60, 76, 194–195t
Lexical–semantic processing tests, 193–201
Lexical–semantic treatment approaches. See also Combined semantic and phonological
treatment approaches
  brain stimulation approaches, 331–332
cognitive neuropsychological approaches, 322–331
linguistic stimulation approach, 310–314, 315f, 316–319, 320t, 321–322
Life Participation Approach to Aphasia (LPAA). See also Social models, 452–453
Lighthouse imagery strategy, 361
Lighting, 449
Liles Communication Test, 212
Limb activation training, 361–362
Limb and head movements, as intention treatment, 392
Limb apraxia, 41, 156–157
Limbic system, 33
Lindamood Phoneme Sequencing Program for Reading, Spelling, and Speech (LiPS). See also
Auditory Discrimination in Depth (ADD), 303
Line bisection tasks, 249, 251
Lingraphica system, 421
Linguistic ambiguity awareness, 341–342
Linguistic disorders assessment of body structure and function
  cognitive ability evaluation during, 266–267
overview of, 166–174
specific tests for, 185, 186–214
test confounds, 214–215
Linguistic disorders treatment. See Activity-focused treatment; Behavioral approaches for
linguistic disorders; Participation-focused treatment; Pharmacotherapy approaches
Linguistic outcomes and prognosis, 215, 216f, 217–221
Linguistic processing, 15, 16f, 17–18, 25, 40
Linguistic Specific Treatment. See Treatment of underlying forms (TUF)
Linguistic stimulation approaches, 300, 310–321, 333–335
Linguistic-theory-motivated approaches, 335–338
LiPS. See Lindamood Phoneme Sequencing Program for Reading, Spelling, and Speech (LiPS)
Literacy. See Health literacy; Reading
Literacy, as a testing confound, 215
Literacy problems. See Reading deficits treatment
Literal paraphasias. See Phonemic or literal paraphasias
Living With Aphasia: Framework for Outcome Measurement (A-FROM), 275s
Location Learning Test, 257
Logopenic progressive aphasia, 52, 53t
Long-term care (LTC) settings, 117, 117f, 282, 479
Long-term memory, 20–22, 23–24, 31–32, 44
LPAA. See Life Participation Approach to Aphasia (LPAA)
LTC. See Long-term care (LTC) settings

M
Magnetic resonance imaging (MRI), 26s, 332
Magnetoeencephalography (MEG), 27s
Maintenance. See Generalization
Malignant brain tumors, 91, 92
Managed care models, 484–486
Mapping therapy, 335–336, 391
Marketing of services, 489–490
MAST. See Mississippi Aphasia Screening Test (MAST)
Maze completion tests, 258
MCST-A. See Multimodal Communication Screening Task for Persons With Aphasia (MCST-A)
MDS. See Minimum Data Set (MDS)
Medicaid. See also Centers for Medicare and Medicaid Services (CMS), 281, 439, 481–482, 484
Medical factors, in prognosis, 218–220
Medical professionals. See also specific type of professional, 447–448
Medical records review, 124–126
Medicare. See also Centers for Medicare and Medicaid Services (CMS)
  case rate system in, 486
documentation and, 488
fee-for-service model and, 484
group treatment and, 436–437, 439
MDS and, 281
overview of, 481
Medications. See also Pharmacotherapy approaches, 216f, 269
Meditation, 458
MEG. See Magnetoencephalography (MEG)
Melodic Intonation Therapy (MIT), 319–321
Memantine, 400f, 408
Memory, 20–24, 31–32
Memory aids. See also External devices, 375–376, 377
Memory books, 428–430
Memory deficits
  AAC and, 420
  anterograde amnesia and, 69
  with aphasia, 43–44
  in dementia, 74–75
  in RHD, 58
  in TBI, 69–70, 71
Memory for Intentions Test (MIST), 255–256
Memory retrieval, 21f, 23–24, 31
Memory tests, 233, 240–241, 252–257
Memory treatment, 367–376
Men. See Gender differences
Meningiomas, 91
Mental Slowness Questionnaire, 229
Mental-state inferencing, 32
Meta-cognitive abilities, 24
Metacognitive training, 358
Metalinguistic awareness. See also Linguistic ambiguity awareness; Topic coherence and cohesion, 340–341
Metalinguistic comments, 200t
Metaphor Training Program (MTP), 343–344
Metastatic brain tumors, 91
Methylphenidate, 399t, 404
Micrographia, 107, 108f
Mild cognitive impairment (MCI), 72, 364, 374, 458
Mild language impairments tests, 190
Mini Inventory of Right Brain Injury (MIRBI), 180
Mini Inventory of Right Brain Injury–Second Edition (MIRBI-II), 140, 176, 180
Minimally conscious state, 66–67
Mini-Mental State Examination (MMSE), 231, 233, 234
Mini-Mental State Examination–Second Edition (MMSE-2), 227, 231, 265
Minimum Data Set (MDS), 281–283, 486
MIRBI. See Mini Inventory of Right Brain Injury (MIRBI)
MIRBI-II. See Mini Inventory of Right Brain Injury–Second Edition (MIRBI-II)
Mississippi Aphasia Screening Test (MAST), 173
MIST. See Memory for Intentions Test (MIST)
MIT. See Melodic Intonation Therapy (MIT)
MMSE. See Mini-Mental State Examination (MMSE)
MMSE-2. See Mini-Mental State Examination–Second Edition (MMSE-2)
Mnemonic strategies, 368–369
Modafinil, 400, 408
Modifications. See also Accommodations; Compensatory strategies
environmental adaptation approaches, 376–377
of environment and task for neglect treatment, 358–360
of physical environment, 448–451
qualitative information from, 142
to social environment, 440–448
in stimulus and test administration, 142
theoretical framework and treatment, 301
of treatment protocols, 319
Modified Wisconsin Card Sorting Test (M-WCST), 260
Monocular eye patching, 359
MOR. See Multiple Oral Rereading (MOR)
Morphemes, 18
Morphosyntactic processing, 17–18, 38, 41, 76
Morphosyntactic processing tests, 202–205
Morphosyntactic treatment approaches, 333–338
Mosquitoes, 93–94
Moss Attention Rating Scale, 229
Motivation, 32, 216, 218
Motor extinction or neglect, 57
Motoric impairments screenings, 153–154, 156–158
MRI. See Magnetic resonance imaging (MRI)
MTP. See Metaphor Training Program (MTP)
Multicomponent Intervention Program, 387
Multidisciplinary involvement. See also Team approach, 5
Multilingual aphasia, 51–52
Multilingual Aphasia Examination, 178
Multilingualism. See also Bilingual speakers, 338–339
Multimodal Communication Screening Task for Persons With Aphasia (MCST-A), 419
Multimodality communication approaches, 415, 441–442
Multiple Oral Rereading (MOR), 324
Multiple sclerosis (MS)
lesion location for, 73
meditation and, 458

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
pharmacotherapy approaches, 399t, 400t
prevalence of, 109
reversible dementia in, 112
symptoms of, 109–110
tests for, 206, 243

M-WCST. See Modified Wisconsin Card Sorting Test (M-WCST)

N
NAB. See Neuropsychological Assessment Battery (NAB)
NAB Mazes Test, 258
NAB Naming Test, 198
Naming. See Anomia
Naming errors, 54
Narrative rules, 18
National Aphasia Association, 422
National Center for Complementary and Alternative Medicine (NCCAM), 457
National Head Injury Foundation, 94
National Institutes of Health (NIH), 94s
National Outcomes Measurement System (NOMS), 281, 282t, 283
Native language, RHD and, 60
Naturalistic Action Test, 157
Naturalistic tests, 242–243, 252, 262–263
N-back tasks, 254, 255f
NCCAM. See National Center for Complementary and Alternative Medicine (NCCAM)
Neck stimulation, 363
Neglect-alert device, 361
Neglect dysgraphia, 58
Neglect dyslexia, 58
Neglect syndrome
   AAC and, 419
dementia and, 74
   environmental factors and, 249
   overview of, 54, 56–58
   as prognostic factor, 222, 269, 270
   right-sided neglect, 43, 68
   TBI and, 68
   TENS and, 462
Neglect tests, 249–252
Neglect treatment, 358–363, 424
Neologisms, 37t, 39, 40t, 50, 200
Neoplasms. See Brain tumors
Neuroanatomy
   in aphasia, 47, 48t, 49, 50
   of cognition, 30–33
   functional outcomes and, 71–72
   of language, 28–29, 30f
Neurobehavioral Functioning Inventory, 167
Neurogenic stuttering, 156s
Neuroleptic medications, 400t, 407–408
Neurological examination procedures, 129t
Neurological incidences, xi
Neurologists, 472
Neuroprotective agents, 90

Neuropsychological Assessment Battery (NAB), 176, 235, 238
Neuropsychologists, 120t, 121s, 122, 152, 226, 366s
Neurotransmitters, 396–398
NIH. See National Institutes of Health (NIH)
NOMS. See National Outcomes Measurement System (NOMS)
Nondeclarative memories. See also specific language speaker, 142–143s, 178, 233, 265
Nonfluent aphasia, 46, 47
Nonfluent progressive aphasia, 202
Nonreversible dementia, 109
Nonstandardized assessment procedures, 476s
Nonverbal cues difficulty, 54, 60, 61, 150
Nonverbal memory tests, 256–257
Nonword syllable same-or-different judgment, 302
Noradrenalin. See also Catecholamine system, 397–398s
Norepinephrine, 398
No responses, 200
Nurses. See also Health-care providers, 474s

O

OASIS. See Outcome and Assessment Information Set (OASIS)
Object Sorting Test, 260
Observations
  in assessments, 122, 133–134, 228–229
  for complicating conditions, 164s
  formal apraxia tests and, 158
  of functional communication, 285
  of participation, 288
  pharmacotherapy approaches and, 396, 405s
  during testing, 167, 171
Occipital lobes, 82f, 83
Occupational therapists, 120t, 122, 152, 226, 366s
OCEBM. See Oxford Centre for Evidence-Based Medicine (OCEBM)
Office of Technology Assessment (OTA), 9, 10
OneQ, 291
Open class words, 202
Open head injuries. See also Traumatic brain injuries (TBI), 96, 97
Optokinetic stimulation, 359
Oral and Written Language Scales—Second Edition (OWLS-2), 176t, 204
Oral Reading for Language in Aphasia (ORLA), 330–331
Organization deficits, 24, 45, 61
Organization tests, 258, 259–260
Orientation level. See also Reality orientation to environment, 128, 230t
Orientation Log, 232
Orthographic input and output lexicons and buffers, 16f, 17

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Orthographic processing, 16f, 17
Orthographic processing tests, 192–193
Orthographic treatment approaches, 307–310, 311r
OTA. See Office of Technology Assessment (OTA)
Outcome and Assessment Information Set (OASIS), 486
Outcome evaluations, 11
Outcomes. See Cognitive outcomes and prognosis; Functional outcomes; Linguistic outcomes and prognosis; Program evaluations
Out-of-network providers, 484s
Outpatient care, 117, 118, 480–481
Output paucity or excess, 61
Overt memory strategies, 424
Oxford Centre for Evidence-Based Medicine (OCEBM), 10, 13f

P
PACE. See Promoting Aphasics’ Communicative Effectiveness (PACE)
Paced Auditory Serial Addition Test, 243
Pacing strategies, 424
Paging system. See Neuropage system
PALPA. See Psycholinguistic Assessments of Language Processing in Aphasia (PALPA)
Pantomime, 417–418
Paragrammatism, 37t, 38
Paraneoplastic syndromes, 92
Paraphasias, 38–39, 40r, 50
Parietal lobes, 81, 82f
Parkinson’s disease (PD)
acupuncture and, 462
complicating conditions in, 152, 156s, 157, 158
lesion location for, 73s
pharmacotherapy approaches, 399t, 400t, 406
prevalence of, 107
prognostic factors in, 269
symptoms of, 74, 75, 76, 108f, 219
TBI incidence and, 95
tests for, 184, 206, 232
Parkinson’s Disease–Cognitive Rating Scale, 232
Participation-focused treatment. See also Activity-focused treatment, 451–457
Participation measures, 275, 286–288
Patching. See Monocular eye patching
Patient and caregiver interviews, 126, 128, 129, 131–133
Patient education. See also Counseling and education
in acute care, 477
assessment results sharing and, 145
awareness training, 377–378, 379r, 380
on memory books, 428–430
on strategy and external device training, 431–432
on topic coherence and cohesion treatment, 347
on treatment purposes, 301s
Patient intake form, 168–170f
Patient Protection and Affordable Care Act (2010), 482, 486, 489

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Patients, as part of team approach, 122
PCAD. See Personal Communication Assistant for Dysphasic People (PCAD)
PD. See Parkinson’s disease (PD)
PECOT approach, 7
Pediatric Test of Brain Injury (PTBI), 176, 182
Perception, 14–15
Perceptual deficits, 54, 55–56, 73–74
Perceptual deficits screenings, 150, 151
Per diem funding, 485
Permanent vegetative state, 66
Perseveration, 75, 381–382, 385
Persistent vegetative state (PVS), 66
Personal Communication Assistant for Dysphasic People (PCAD), 421
Personal factors, 4
Personal information cards, 422
Personalized cues, 314
PET. See Positron emission tomography (PET)
Pharmacotherapy approaches, 395–407
Philadelphia Brief Assessment of Cognition, 232
Phoneme discrimination, 302
Phoneme-grapheme matching, 302
Phonemes, 15
Phonemically related paraphasias, 200
Phonemic or literal paraphasias, 37, 39, 40, 199–200
Phonetic perception tests, 191
Phonological input and output lexicons and buffers, 15, 16, 17
Phonological processing, 15, 16, 17
Phonological processing tests, 190–193
Phonological treatment approaches. See also Combined semantic and phonological treatment
approaches, 302–307, 316, 329, 330
Phonology tests, 190–192
Photocopy task, 262
Physicians. See Health-care providers; Neurologists
Physostigmine, 400, 402
Pick’s disease, 52, 73, 105
Pictionary, 413, 414
Piracetam, 400, 402, 406
Pitch analysis system, 306
Pitch discrimination deficits, 54, 55, 150
Planning deficits, 24, 32, 45, 75
Planning deficits treatment, 385–386
Planning tests, 258–259
PMR. See Progressive muscle relaxation (PMR)
Porch Index of Communicative Ability, 173, 176
Porteus Maze Test, 258
Positive communication skill training. See under Communication partners
Positron emission tomography (PET), 27s
Post-traumatic amnesia (PTA), 67, 68
PPA. See Primary progressive aphasia (PPA)
PPS. See Prospective payment systems (PPS)
Practice, generalization and, 392
From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Practice-based evidence, 11
Pragmatic Protocol, 211–212
Pragmatics and discourse impairment treatment, 128, 339–351
Pragmatics and discourse processing, 18, 60–63, 70, 71, 215
Pragmatics and discourse tests, 190, 205–213
Pre-authorization of services, 484
Predictive validity, 136t, 137
Pre-existing conditions. See Complicating conditions
Preferred provider models, 484–486
Prefrontal cortex, 31
Premorbid abilities. See also Case histories; Patient and caregiver interviews, 119, 216t, 218, 268, 269
Premorbid intelligence, 218, 268
Preprocessed evidence, 11
Presbycusis, 148
Prevention and wellness activities, 470–472s
Primary brain damage, 97–98, 97–99
Primary brain tumors, 91
Primary care, 470
Primary progressive aphasia (PPA), 39f, 52, 53t
Prism lenses, 359
Private insurers. See also Third-party payers, 116, 299–300, 481
Problem solving, 24, 32, 45, 70
Problem-solving tests, 258, 262–263
Procedural memory, 21f, 22, 31, 70, 74
Process measures, 279–280
Production deficits, 305–307, 313–322, 324–328, 330, 344–345
Productivity targets, 486
Professional guidelines, for assessment procedures, 120–121
Prognostic factors. See also Screenings
in acute care, 477
for cognitive outcomes, 221–222, 267–270
for linguistic outcomes, 175, 215, 216t, 217–221
Program evaluations, 279–283
Progressive muscle relaxation (PMR), 458
Progressive neurological diseases. See also Dementia; specific condition
complicating conditions in, 156s, 157, 158
diagnosing, 106–107s
overview of, 101–102
prognostic factors in, 219, 270
tests for, 232
Progressive nonfluent aphasia, 52, 53t, 105
Progressive supranuclear palsy, 73s
Promoting Aphasic’s Communicative Effectiveness (PACE), 212, 432–436
PROMPT (Prospective Memory Process Training). See also Spaced retrieval, 370–371
Propopagnosia, 73, 152
Prosody treatment, 304–307, 446t
Prosopagnosia, 55f, 73, 152
Prospective memories, 21
Prospective Memory Process Training. See PROMPT (Prospective Memory Process Training)
Prospective payment systems (PPS), 485
Proxemics, inappropriate, 54
Proxy ratings, 163
Pseudodementia, 111, 112
Psychiatric disorders screenings, 158–160, 161–162, 163
Psychiatric illnesses, 95, 220, 269
Psychiatric well-being measures, 161–162
Psycholinguistic Assessments of Language Processing in Aphasia (PALPA), 191, 193, 201, 202, 203, 204
Psychologists. See also Neuropsychologists, 121, 226
Psychometric properties and considerations, 135–138
PTA. See Post-traumatic amnesia (PTA)
PTBI. See Pediatric Test of Brain Injury (PTBI)
Pure agraphia, 51
Pure alexia, 51
Pure aphasia, 51
Pure word deafness, 51, 150
Putamen, 30f, 33, 109
Putney Auditory Comprehension Screening Test, 196
PVS. See Persistent vegetative state (PVS)
Pyramids and Palm Trees, 195

Q
QOL-AD. See Quality of Life in Alzheimer’s Disease (QOL-AD)
QOLIBRI. See Quality of Life After Brain Injury (QOLIBRI)
Qualitative information, in tests, 121s, 141–142
Quality assurance. See also Program evaluations, 487, 488–489
Quality of Communication Life Scale (ASHA QCL), 293
Quality of Life After Brain Injury (QOLIBRI), 292
Quality of Life in Alzheimer’s Disease (QOL-AD), 293
Quality-of-life measures, 275, 288–294
Question-framing. See PECOT approach
Quick Assessment for Apraxia of Speech, 153
Quick Assessment for Dysarthria, 154

R
Racial differences. See also Ethnic differences; Ethnocultural variables, 85, 109
Random paraphasias, 39, 40t, 200
Rapid Assessment of Problem Solving, 262
Raven’s Progressive Matrices, 262
RBANS. See Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)
RBMT-III. See Rivermead Behavioral Memory Test (RBMT-III)
RCBA-2. See Reading Comprehension Battery for Aphasia—Second Edition (RCBA-2)
Reading, 17, 250
Reading deficits treatment. See also Auditory Discrimination in Depth (ADD), 307–308, 324, 346, 443s
Reading tests, 191, 192–193, 207
Reality orientation groups, 437–438
Reality orientation to environment, 449–450
Real world tests. See also Memory for Intentions Test (MIST); Non-standardized assessment procedures, 242–243, 252, 262–263
From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Reasoning. See also Clinical reasoning, 32, 45
Reauditorization, 312
Recall, recognition versus, 23
Receptive aphasia. See also Wernicke’s aphasia, 46–47
Recognition, recall versus, 23
Reference markers, 210–211
Referrals
   acquisition of, 123–124
   for caregivers, 143
   clinical competency to advocate for, 299–300
   counseling and education and, 466
   marketing and, 490
   sources of, 470, 472, 473, 475
Rehabilitation, in acute care, 475, 477
Rehabilitation Act (1973), 482
Rehabilitation settings. See also Inpatient rehabilitation; Long-term care (LTC) settings;
   Outpatient care; Skilled nursing facilities (SNFs), 117
Reimbursement issues. See also Health-care funding models, 116s, 439, 490
Relational words, 202
Relaxation therapy, 457–459
Relevance of information. See Discourse informativeness; Topic coherence and cohesion; Topic
management
Reliability, in formal tests. See also specific tests, 135–136
Remediation of body structure and function. See Behavioral approaches for cognitive disorders;
   Behavioral approaches for linguistic disorders; Pharmacotherapy approaches
Remembering. See Memory retrieval; Word retrieval
Reminiscence activities, 436
Repair strategies, 415, 433, 442–443
Repetible Battery for the Assessment of Neuropsychological Status Update (RBANS), 176t, 185
Repetitions. See also Perseveration, 40, 49, 50, 200
Repetition tasks, 313–314
Repetitive transcranial magnetic stimulation (rTMS), 331–332, 362s
Report bias, 133, 229, 264–265
Research funding, 94s
Resources. See Books; Community resources; Support groups
Resource utilization groups (RUGs), 486
Response Elaboration Training (RET), 318
Restorative versus adaptive treatment, 478, 479, 480
RET. See Response Elaboration Training (RET)
Retrieval. See Memory retrieval; Word retrieval
Retrograde amnesia, 69
Retrograde memories, 22
Retrospective confidence judgments, 265
Reversible dementia, 111–112
Revised Token Test (RTT), 196, 203
Rey-Osterrieth Complex Figure Test, 256
Rey’s Visual Design Learning Test (RVDLT), 256
RHD. See Right hemisphere disorders (RHD)
RIC Evaluation of Communication Problems in Right Hemisphere Dysfunction–Revised, 177t
Right frontal lobe, 31
Right hemisphere, 30–31, 32f

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Right hemisphere disorders (RHD)
assessment goals in, 117, 119
complicating conditions after, 150, 152, 157
crossed aphasia, 51
deficits associated with, 55–63
functional measures for, 284
functional outcomes of, 58, 59, 226
overview of, 52–54
patient interview and limitations from, 128
prevalence of, 53, 56, 59
prognostic factors in, 220, 269
psychiatric disorders screenings an, 160
TBI as, 68
Right hemisphere disorder tests. See also Nonverbal memory tests
dementia tests versus, 183
overview of, 176–177, 180–181, 185, 206, 212
supplementary test use in, 190
Right hemisphere disorder treatment
APT, 364
CAM, 462, 464
communication partner training, 445–447
in groups, 437–438
pharmacotherapy approaches, 399, 406
pragmatics and discourse impairment treatment, 341
pragmatics and discourse-level impairment treatment, 342, 344, 348
suprasegmental impairments treatment, 304–307
Right Hemisphere Language Battery–Second Edition, 177
Right posterior parietal cortex, 31
Right prefrontal cortex, 31
Right-sided neglect. See also Neglect syndrome, 43, 68
RIPA. See Ross Information Processing Assessment (RIPA)
RIPA-2, 238
RIPA-Geriatric:2 (RIPA-G:2), 238
Ritalin, 399, 404
Rivastigmine, 400, 406
Rivermead Behavioral Memory Test (RBMT-III), 240–241
Role playing, 340, 349, 350, 378, 436
Ross Information Processing Assessment (RIPA), 238
Rote rehearsal, 369
rTMS. See Repetitive transcranial magnetic stimulation (rTMS)
rTPA (recombinant tissue plasminogen activator), 89–90, 472–473
RTT. See Revised Token Test (RTT)
Ruff Figural Fluency Test (RFFT), 263–264
RUGs. See Resource utilization groups (RUGs)
RVDLT. See Rey’s Visual Design Learning Test (RVDLT)

S
SADQH. See Stroke Aphasic Depression Questionnaire (SADQH)
SADQH-I, 163
SADS. See Stroke and Aphasia Depression Scale (SADS)
From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Satisfaction With Life Scale (SWLS), 290–291
SCA. See Supported Conversation for Adults With Aphasia (SCA)
Scales of Cognitive and Communicative Ability for Neurorehabilitation (SCCAN), 177t, 185
Scales of Cognitive Assessment for Traumatic Brain Injury (SCATBI), 182
SCAN-3 Tests for Auditory Processing Disorders in Adolescents and Adults, 150, 151t
SCATBI. See Scales of Cognitive Assessment for Traumatic Brain Injury (SCATBI)
SCCAN. See Scales of Cognitive and Communicative Ability for Neurorehabilitation (SCCAN)
ScreeLing, 173
Screenings
for caregivers, 143
case histories and observations as, 124
cognitive disorders and, 229–234
developing one’s own, 171–172
inappropriate use of, 234
linguistic disorders and, 171–174, 178
in LTC settings, 479
for motoric deficits, 153–154, 155t, 156–158
for perceptual deficits, 150, 151t, 152
precautions in using, 171, 172, 173, 174s
for psychiatric disorders, 158–160, 161–162t, 163
for sensory deficits, 148–150
SLPAs and, 487
Scripts. See Conversational script training
Secondary brain damage, 100
Secondary care, 472
SEE. See Signed Exact English (SEE)
Segmental impairments treatment, 302–304
Segmental subsystem, 15, 190–191
Selective attention, 20, 20t
Selective attention tests, 248–249
Selective serotonin reuptake inhibitors (SSRIs), 400t, 407, 408
Self-advocacy, 379
Self-awareness, 32, 222, 270
Self-Awareness of Deficits Interview, 264
Self-cue approach, 385–386, 424
Self-monitoring. See also Awareness training, 24, 45, 128, 222
Self-monitoring tests, 258, 263–265
Self-regulation. See also Meta-cognitive abilities, 32
Semantic dementia, 52, 53t
Semantic elaboration, 369
Semantic Feature Analysis (SFA). See also Verb Network Strengthening Treatment (VNeST),
325–326
Semantic memory, 21–22, 31
Semantic paraphasias, 37t, 39, 40t, 200, 200t
Semantic processing. See Lexical–semantic processing
Semantic treatment approaches. See also Combined semantic and phonological treatment approaches, 322–331
Senior centers, 457
Sensitivity, in psychometrics, 137
Sensorimotor issues, gestures and, 41
Sensory deficits screenings, 148–150

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Sensory deprivation, 459
Sensory extinction to simultaneous stimulation, 57
Sensory stimulation, 459–461
Sentactics, 338
**Sentence Production Program for Aphasia (SPPA),** 333–335
Sentence repetition tasks, 390
SentenceShaper, 420
Serial lesion effect, 91–92
Serotonin, 398
Sertraline, 400
Severe Impairment Battery (SIB), 177, 184–185, 238–239
Short-term memory, 21f, 22, 40
SIB. **See Severe Impairment Battery (SIB)**
**Sickness Impact Profile (SIP),** 289–290, 291
Signed Exact English (SEE), 416
Sign languages. **See also** Gestures; Pantomime, 213, 416–417
Silent pauses, 200, 200
Singing. **See** Melodic Intonation Therapy (MIT)
Single photon emission computed tomography (SPECT), 27
SIP. **See** Sickness Impact Profile (SIP)
SIS. **See** Stroke Impact Scale (SIS)
Skilled nursing facilities (SNFs), 478–479, 486
SLP assistants (SLPAs), 487
SmallTalk, 421
Smartphones, 420, 421
SNFs. **See** Skilled nursing facilities (SNFs)
Snoezelen, 459–460
Social activity, as prognostic factor, 269
Social cognition, 62–63
Social conveniences treatment, 348–351
Social Language Development Test–Adolescent, 209
Social models. **See also** Life Participation Approach to Aphasia (LPAA), 453–454
Social skills intervention groups, 350–351
Social workers, 486
Socioeconomic status, 95
Software and applications, as treatment activities, 350–354, 363, 384, 388, 389
Soldiers. **See also** Blast injuries; Veterans, 94
Somatosensory screenings, 149
Sony IC Recorder (ICD-50), 428
Sound-to-letter rules, 16f, 17
Spaced retrieval. **See also** PROMPT (Prospective Memory Process Training), 371, 372, 375, 391
Spanish speakers. **See also** Non-English speakers
  quality-of-life measures for, 292
  screenings for, 173
  tests for, 178, 185, 197, 243, 265
Span tasks, 253
Specificity, in psychometrics, 137
SPECT. **See** Single photon emission computed tomography (SPECT)
Speech acts, 211–212
Speech discrimination treatments, 302
Speech fluency, 37–38, 39f, 46

*From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.*
Speech perception tasks. See also Deblocking activities, 313
Speech-to-text capability, 420
Spelling deficits treatment. See also Auditory Discrimination in Depth (ADD), 308–310, 311
Spouses. See Caregivers
SPPA. See Sentence Production Program for Aphasia (SPPA)
SS-QOL. See Stroke-Specific Quality of Life Scale (SS-QOL)
SSRIs. See Selective serotonin reuptake inhibitors (SSRIs)
Standardization, in formal tests, 137–138
Standardized tests. See Formal test procedures; Tests; specific tests
Stereotypy, 39, 40
Stimulability, as prognostic factor, 221
Story retelling tasks, 255, 347
Strategic learning, 69, 369
Stroke and Aphasia Depression Scale (SADS), 163
Stroke and Aphasia Quality of Life Scale–39 (SAQOL-39), 292
Stroke Aphasic Depression Questionnaire (SADQH), 163
Stroke belt, 85
Stroke Impact Scale (SIS), 287
Strokes. See also Aphasia; Cerebral vascular system; Vascular dementia
causes of, 86
functional outcomes of, 226
overview of, 80
participation measures for, 287
prevalence of, 80
prognostic factors in, 219, 222, 270
quality-of-life measures for, 292
risk factors in, 84–85, 87
sensory stimulation and, 460–461
types of, 85–89
Stroke-Specific Quality of Life Scale (SS-QOL), 292
Stroke support groups, 455, 456
Stroke survival, 89
Stroke treatment. See also Aphasia treatment; Right hemisphere disorder treatment, 89–90, 373
Stroop tasks, 261
Study designs, evidence quality and, 10
Stuttering, 156
Subcortical aphasia, 50–51
Subcortical brain structures, 30
Subcortical dementia, 73
Substance abuse, 95, 110, 111, 143
Substantive words, 202
Superior longitudinal fasciculus, 29
Supported Conversation for Adults With Aphasia (SCA), 443–444, 454
Support groups, 434, 455, 456, 457
Supporting Partners of People With Aphasia in Relationships and Conversation, 210
Support levels, as prognostic factors. See also Caregiver attitudes, 269
Suppression (SUP), 342
Supramarginal gyrus, 28–29
Suprasegmental impairments treatment, 304–307

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Suprasegmental subsystem, 15, 190, 192
Sustained attention, 20, 31, 62
Sustained attention tests, 248
Swallowing function and services, 473, 479, 489
SWLS. See Satisfaction With Life Scale (SWLS)
Symbols, 14
Syntactic processing. See Morphosyntactic processing
Syntax, 18, 38

T
Tactile-kinesthetic treatment, for reading deficits, 307–308
TAP. See Treatment for Aphasic Perseveration (TAP)
TASIT. See The Awareness of Social Interference Test–Revised (TASIT)
Tasks of Executive Control, 261–262
tDCS. See Transcranial direct current stimulation (tDCS)
TEA. See Test of Everyday Attention (TEA)
Teachers, 226
Team approach, 119–123, 226, 366s, 478, 480
Team education, 123–124
Telephone Interview for Cognitive Status (TICS), 231–232
Telephones. See iPhones
Telephone Test, 253
Temporal lobes
  acetylcholine and, 402
  Alzheimer’s disease and, 103
  blood supply for, 81, 82f, 83
  Coup and contrecoup injuries in, 98
  functions of, 31, 32f
TENS. See Transcutaneous electrical nerve stimulation (TENS)
Tertiary care, 472
Test confounds. See also Complicating conditions, 214–215, 228–229, 265–266, 274
Test for Reception of Grammar–Second Edition, 203
Test of Adolescent and Adult Language–Fourth Edition (TOAL-4), 182–183
Test of Adolescent and Adult Word-Finding, 204
Test of Everyday Attention (TEA), 239–240, 249
Test of Language Competence–Expanded Edition (TLC-E), 206
Test of Nonverbal Intelligence–Fourth Edition (TONI-4), 262
Test of Oral and Limb Apraxia, 157
Test of Pragmatic Language–Second Edition (TOPL-2), 209
Test of Problem Solving–Adolescent: Second Edition, 262
Test of Silent Reading Efficiency and Comprehension, 207
Test of Upper Limb Apraxia, 213
Test of Variables of Attention–8, 248
Test of Verbal Conceptualization and Fluency (TVCF), 263
Test of Visual Field Attention, 251
Test of Written Language–Fourth Edition (TOWL-4), 208–209
Test-retest reliability, 136, 136f
Tests. See also specific tests
  advantages to using, 140
  language sampling in, 198–201

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
precautions in using, 140–141, 191, 193, 212, 241, 257–258
qualitative considerations in, 141–142
reliability and validity in, 135–137
selection of, 140–141
Text messaging, 420, 428
Text-to-speech capability, 420, 428
Thalamus
blood supply for, 83
functions of, 29, 30, 30f, 31, 33
Korsakoff’s disease and, 110
*The Awareness of Social Interference Test–Revised* (TASIT), 207–208
Theme identification, 61
Theory of Mind, 62–63
Therapeutic hypothermia, 90
Therapeutic nihilism, 123
Therapy caps. See Caps or limits
*The WORD Test–Second Edition: Adolescent* (TWT), 198
Third-party payers. See also Private insurers; Reimbursement issues, 281, 439, 483–484, 486
Thrombosis, 86, 87
Thrombotic strokes, 86–87
TICS. See Telephone Interview for Cognitive Status (TICS)
Tinnitus, 148
TLC-E. See Test of Language Competence–Expanded Edition (TLC-E)
TOAL-4. See Test of Adolescent and Adult Language–Fourth Edition (TOAL-4)
TOL:RV. See Tower of London DX: Research Version (TOL:RV)
TONI-4. See Test of Nonverbal Intelligence–Fourth Edition (TONI-4)
Topic coherence and cohesion, 345–347
Topic management, 62, 71, 76, 446f
TouchSpeak, 421
Tower of London DX: Research Version (TOL:RV), 258–259
Tower tests, 258–259
TOWL-4. See Test of Written Language–Fourth Edition (TOWL-4)
Tracine, 399f, 406
*Trail Making Test*, 248–249, 262, 263
Transaction, 454
Transcortical aphasia, 48f, 49, 50
Transcranial direct current stimulation (tDCS), 331–332, 362s
Transcranial magnetic stimulation, 26–27s
Transcutaneous electrical nerve stimulation (TENS), 462
Transfer of learning. See Generalization
Transient ischemic attack (TIA), 87–88
Translation disorders, 52
Traumatic brain injuries (TBI)
anosognosia and, 228
axonal shearing in, 99f
causes of, 95
complicating conditions after, 148, 149, 150, 153, 154, 156s, 158
coup and contrecoup in, 99f
functional measures for, 284, 286
functional outcomes of, 66–72, 97, 100, 226

*From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.,
by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.*
participation measures for, 286
pathophysiological consequences of, 97–98, 99f, 100
patient interview and limitations from, 128
prevalence of, 94, 94s
prognostic factors in, 216t, 217, 219, 220, 221, 269, 270
psychiatric disorders screenings and, 160
quality-of-life measures for, 292
recovery stages in, 64–67
research funds for, 94s
risk factors in, 95
symptoms of, 67–72
types of, 95–97
Traumatic brain injury screenings, 174
Traumatic brain injury tests
auditory comprehension, 196
cognitive abilities, 232, 238, 242, 243
cognitive-communication abilities, 185
dementia tests versus, 183, 184
discourse cohesion analysis in, 211
functional measures of, 281
lexical-semantic production, 198
overview of, 176–177t, 181–183
pragmatic and discourse abilities, 206, 208
Traumatic brain injury treatment
attention treatment, 363
CAM, 458, 460–461, 462, 463
communication partner training, 445–447
executive function treatment, 380, 383, 384
in groups, 437–438
memory treatment, 370, 371, 373, 374
pharmacotherapy approaches, 399t, 400t, 404–405, 406, 408
pragmatics and discourse impairment treatment, 341, 348, 349, 350
SFA, 324–326
suprasegmental impairments treatment, 304–307
Treatment. See specific approaches or treatments
Treatment confounds. See Complicating conditions
Treatment efficacy. See also Functional outcomes; specific approaches or treatments; specific treatment approaches and programs, 9–10, 274, 279–283, 487
Treatment efficiency. See also Group treatment, 10, 351, 487
Treatment for Aphasic Perseveration (TAP), 381
Treatment for Wernicke’s Aphasia (TWA), 311–312
Treatment intensity, 354–355
Treatment of underlying forms (TUF), 336–338
Treatment outcomes. See also Functional outcomes, 19
Treatment planning. See also Ethnocultural variables
for bilingualism, 338–339s
different intervention strategies in, 328–329s
understanding theoretical framework behind, 300, 301s
use of case histories for, 124
use of patient and caregiver interviews for, 126, 128
TUF. See Treatment of underlying forms (TUF)
Tumors. See Brain tumors
Turn-taking issues, 71, 348, 442t, 446t
TVCF. See Test of Verbal Conceptualization and Fluency (TVCF)
TWA. See Treatment for Wernicke’s Aphasia (TWA)
Twitter, 443s
TWT. See The WORD Test—Second Edition: Adolescent (TWT)

U
Unilateral spatial neglect. See also Neglect syndrome, 56

V
Validity, in formal tests. See also specific tests, 136–137
VAMS. See Visual Analog Mood Scales (VAMS)
Vanishing cues training approach. See also Chaining techniques, 375, 391
Variation, generalization and, 392
Vascular dementia. See also Dementia, 110–111, 219, 399t, 400t, 406, 408
VASES. See Visual Analogue Self-Esteem Scale (VASES)
VAST. See Verb and Sentence Test (VAST)
VAT. See Visual Action Therapy (VAT)
VATA-L. See Visual-Analogue Test Assessing Anosognosia for Language (VATA-L)
VCIU. See Voluntary Control of Involuntary Utterances (VCIU)
Vegetative state, 65–66
Verbal asomatognosia, 59
Verbal fluency tests, 263
Verbal mediation training, 385, 424
Verbal memory tests, 252–256
Verbal organization, 369
Verbal output, AAC and, 422
Verbal span tasks, 253
Verb and Sentence Test (VAST), 202, 203, 204
Verb Network Strengthening Treatment (VNeST). See also Semantic Feature Analysis (SFA), 326–328
Vertebrobasilar arterial system, 80–81, 83–84
Vestibular organ excitation, 359
Veterans. See also Soldiers, 148
Vibrotactile stimulation, 359
Video recordings
  in awareness training, 377–378, 380
  in communication partner training, 447
  lexical-semantic treatments and, 314, 322
  in memory treatment, 368, 379t
  pragmatics and discourse-level impairments treatment and, 346, 348, 349
Vietnamese speakers, 265
Vigilance. See Sustained attention
Vigil Continuous Performance Test, 248
Virtual Library Task (VLT), 242
Virtual reality exercise program, 463
Vision screenings, 148–149
Visual Action Therapy (VAT), 417–418
Visual agnosias, 55t, 152

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
Visual Analog Mood Scales (VAMS), 163
Visual Analogue Self-Esteem Scale (VASES), 163
Visual-Analogue Test Assessing Anosognosia for Language (VATA-L), 264
Visual imagery. See also Guided imagery (GI), 361, 368–369
Visual object agnosia, 152
Visual perceptual deficits screenings, 151t, 152
Visual Scene Displays (VSD), 419
Visuospatial discrimination, Alzheimer's disease and, 73
Visuospatial environment, 449–450
Visuospatial neglect. See also Hemi-inattention, 56
VLT. See Virtual Library Task (VLT)
VNeST. See Verb Network Strengthening Treatment (VNeST)
Vocation, functional outcomes and, 226
Vocational rehabilitation centers, 457
Voluntary Control of Involuntary Utterances (VCIU), 317, 381
Volunteers, 440, 441, 444
VSD. See Visual Scene Displays (VSD)

W

WAB-R. See Western Aphasia Battery–Revised (WAB-R)
WAIS-IV. See Wechsler Adult Intelligence Scales (WAIS-IV)
Wandering, 450
Watershed zones, 84
WCST. See Wisconsin Card Sorting Test (WCST)
Wechsler Adult Intelligence Scales (WAIS-IV), 235, 253
Wechsler Memory Scale (WMS-IV), 240, 255, 256, 257
Wellness activities. See Prevention and wellness activities
Wernicke's aphasia, 48t, 49, 221, 462
Wernicke's area, 28–29, 83, 103
Wessex Head Injury Matrix, 238
Western Aphasia Battery–Revised (WAB-R), 47, 173, 175, 177, 177t, 263
West Nile Virus, 93–94
Wheelbarrow test, 262
WHO. See World Health Organization (WHO)
Wide Range Achievement Test–Fourth Edition, 198
Wilson Reading System, 303
Wilson’s disease, 73s
Wisconsin Card Sorting Test (WCST), 259–260, 263
WMS-IV. See Wechsler Memory Scale (WMS-IV)
Women. See Gender differences
Word blindness. See Pure alexia
Word deafness. See Pure word deafness
Word meaning suppression, 62
Word-picture matching, 302
Word prediction, 420
Word retrieval. See also Lexical-semantic processing, 76, 391
Word retrieval error analyses, 199–201
Workbooks, as treatment activities, 351–354, 388, 389t
Working memory

From Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.
aphasia and, 44
definition of, 21f, 22–23
neural bases of, 31
as prognostic factor, 222
RHD and, 58
TBI and, 69
Working memory tests, 253–256
World Health Organization (WHO). See International Classification of Functioning, Disability, and Health (ICF)
Writing treatment. See Orthographic treatment approaches
Written language disruptions
in aphasia, 38, 39f, 40–41, 42t
in dementia, 75, 76
neglect and, 250
orthographic processing and, 17
in Parkinson’s disease, 108f
in RHD, 54, 58
social media use and, 443s
tests of, 192–193
Written word–auditory word matching, 302
WRMT-III. See Woodcock Reading Mastery Tests–Third Edition (WRMT-III)